Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass: Complete Statistical AnalysisIndependent statistical analysis of Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PERSEUS SVIndependent statistical analysis of TAXUS PERSEUS Small Vessel: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00489541).
- Persica 002 Phase 1b PP353 vs Placebo in the Treatment of Low Back Pain: Complete Statistical AnalysisIndependent statistical analysis of Persica 002 Phase 1b PP353 vs Placebo in the Treatment of Low Back Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PERSISTIndependent statistical analysis of Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01358357).
- PersistIndependent statistical analysis of Psychosocial Pain Management to Improve Opioid Use Disorder Treatment Outcomes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04433975).
- PERSISTIndependent statistical analysis of Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade: primary endpoint results, effect estimate with…
- PERSIST-AVRIndependent statistical analysis of Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02673697).
- Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines: Complete Statistical AnalysisIndependent statistical analysis of Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines: primary endpoint results, effect estimate with confidence interval, sample-size…
- Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®: Complete Statistical AnalysisIndependent statistical analysis of Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®: primary endpoint results, effect estimate with confidence interval, sample-size…
- Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia: Complete Statistical AnalysisIndependent statistical analysis of Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Persistence of Protection by Shingrix: Complete Statistical AnalysisIndependent statistical analysis of Persistence of Protection by Shingrix: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04169009).
- Personalised HTO Versus Generic HTO Virtual Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of Personalised HTO Versus Generic HTO Virtual Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03419598).
- Personalized Feedback for Distress Intolerant Smokers: Complete Statistical AnalysisIndependent statistical analysis of Personalized Feedback for Distress Intolerant Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03918031).
- Personalized Warfarin Dosing by Genomics and Computational Intelligence: Complete Statistical AnalysisIndependent statistical analysis of Personalized Warfarin Dosing by Genomics and Computational Intelligence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00872079).
- PERSPECTIVEIndependent statistical analysis of Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction: primary endpoint results, effect estimate with confidence…
- Pertussis Infection in Adolescents and Adults With Prolonged Cough: Complete Statistical AnalysisIndependent statistical analysis of Pertussis Infection in Adolescents and Adults With Prolonged Cough: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01597687).
- PERUSEIndependent statistical analysis of A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer: primary…
- PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer: Complete Statistical AnalysisIndependent statistical analysis of PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02023996).
- PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PET-CRAIndependent statistical analysis of Imaging the Neurobiology of a Behavioral Treatment for Cocaine Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00376558).
- PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- PETITIndependent statistical analysis of Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size…
- PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer: primary endpoint results, effect estimate with confidence…
- PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine: Complete Statistical AnalysisIndependent statistical analysis of PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PF-04634817 Renal Impairment Study: Complete Statistical AnalysisIndependent statistical analysis of PF-04634817 Renal Impairment Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01791855).
- PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A: Complete Statistical AnalysisIndependent statistical analysis of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02492984).
- PF-06669571 In Subjects With Idiopathic Parkinson’s Disease: Complete Statistical AnalysisIndependent statistical analysis of PF-06669571 In Subjects With Idiopathic Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02565628).
- PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial): Complete Statistical AnalysisIndependent statistical analysis of PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05780541).
- PFA and SPFIndependent statistical analysis of Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01001975).
- PFAS Exposure and Immune Response to Vaccination in Adults: Complete Statistical AnalysisIndependent statistical analysis of PFAS Exposure and Immune Response to Vaccination in Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06588530).
- Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00280735).
- Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo: Complete Statistical AnalysisIndependent statistical analysis of Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo: primary endpoint results, effect estimate with confidence interval, sample-size…
- Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00590902).
- Ph II Study of Azacitidine in Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Ph II Study of Azacitidine in Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00569660).
- PH-HFpEFIndependent statistical analysis of Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM: Complete Statistical AnalysisIndependent statistical analysis of Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00597493).
- Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure: Complete Statistical AnalysisIndependent statistical analysis of Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- PhantomLimbIndependent statistical analysis of Epidural Spinal Cord Stimulation for Sensory Restoration and Phantom Limb Pain in Upper-Limb Amputees: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PHARLAPIndependent statistical analysis of Open Lung Ventilation in ARDS: The PHARLAP Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01667146).
- Pharmacist Intervention to Improve Smoking Cessation: Complete Statistical AnalysisIndependent statistical analysis of Pharmacist Intervention to Improve Smoking Cessation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06943287).
- Pharmacists and Pharmacy Technicians to Improve Admission Medication History Accuracy: Complete Statistical AnalysisIndependent statistical analysis of Pharmacists and Pharmacy Technicians to Improve Admission Medication History Accuracy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02026453).
- Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products: Complete Statistical AnalysisIndependent statistical analysis of Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04183491).
- Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01852214).
- Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1: Complete Statistical AnalysisIndependent statistical analysis of Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pharmacogenetics of Alcohol: Treatment Implications: Complete Statistical AnalysisIndependent statistical analysis of Pharmacogenetics of Alcohol: Treatment Implications: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00734656).
- Pharmacogenetics of Doxazosin for Cocaine Dependence: Complete Statistical AnalysisIndependent statistical analysis of Pharmacogenetics of Doxazosin for Cocaine Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01145183).
- Pharmacogenetics of Nicotine Addiction Treatment: Complete Statistical AnalysisIndependent statistical analysis of Pharmacogenetics of Nicotine Addiction Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01314001).